Ceftolozane-tazobactam therapy for multidrug-resistant Pseudomonas aeruginosa infections in patients with hematologic malignancies and hematopoietic-cell transplant recipients

Morgan Hakki, James S. Lewis

Research output: Contribution to journalArticle

7 Scopus citations

Abstract

Multidrug-resistant (MDR) Pseudomonas aeruginosa infection causes significant mortality among patients with hematologic malignancies and hematopoietic-cell transplant recipients. Ceftolozane-tazobactam (C-T) is a novel therapeutic option for MDR-P. aeruginosa infections but clinical experience in these patients is limited. We report favorable clinical outcomes and lack of limiting toxicities using C-T monotherapy to treat invasive MDR-P. aeruginosa infections in these patient populations.

Original languageEnglish (US)
Pages (from-to)1-4
Number of pages4
JournalInfection
DOIs
StateAccepted/In press - Feb 19 2018

    Fingerprint

Keywords

  • Ceftolozane-tazobactam
  • Hematologic malignancy
  • Hematopoietic-cell transplant
  • Pseudomonas aeruginosa

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Cite this